Nanomedical Diagnostics Founder and CTO to Highlight Launch of World’s First Commercialized Graphene Biosensor at the Graphene World Summit

Share Article

Leading nanotechnology expert Dr. Brett Goldsmith will share graphene’s key role in AGILE R100, an all-electronic, label-free binding assay

Dr. Brett Goldsmith, CTO of Nanomedical Diagnostics, a company launching graphene biosensor assays

Dr. Brett Goldsmith, Founder and CTO of Nanomedical Diagnostics

Graphene has made it possible to link biology directly with electronics for the first time, bringing an entire world of new capabilities.

Dr. Brett Goldsmith from Nanomedical Diagnostics, a biotech company driving the use of graphene biosensor assays in life science research and diagnostics, will present a session called “Graphene: Uniting Biology and Electronics” at the Graphene World Summit on September 19 and 20.

“I’m excited to share the commercialization of the new graphene-based AGILE R100 biosensor with the nanotechnology community that knows the properties of the material so well,” says Founder and CTO Dr. Goldsmith. “Graphene has made it possible to link biology directly with electronics for the first time, bringing an entire world of new capabilities to drug discovery and life science research.”

Dr. Goldsmith’s talk focuses on the benefits AGILE technology brings to the drug discovery process over current methods. In developing pharmaceutical therapeutics, researchers need to understand the interaction between target proteins and prospective drug compounds. However, current magnetic or optical technologies such as nuclear magnetic resonance (NMR) spectroscopy and surface plasmon resonance (SPR) are difficult to use and slow down the drug discovery process. All-electronic AGILE technology unites biological interactions with the speed and high throughput of electronics, providing measurement and detection capabilities beyond NMR and SPR, at greater speed and lower cost.

“Gaining accurate interaction and binding measurements can be fraught with hurdles,” continues Dr. Goldsmith. “In addition to slowing down the drug discovery process, NMR and SPR struggle with small molecules, small sample sizes, high concentrations, and measurement in DMSO. Because of the intrinsic properties of graphene, AGILE R100 has no lower size limit for detection, needs only 0.5 ng of capture molecule material, and can measure high concentrations in up to 10% DMSO. AGILE technology not only matches current techniques, it surpasses them, thanks to graphene.”

AGILE R100 is available for commercial sale, for research use only. For more information, visit

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough all-electronic assay that provides real-time, label-free kinetic binding and concentration data. The AGILE biosensor chips at the heart of the assay leverage graphene, a highly sensitive nanomaterial, to link biology directly with electronics for the first time, delivering the unique ability to sense small molecules with no lower size limit in complex media such as DMSO, and use unprecedentedly small amounts of sample.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website